Study of IAP0971 plus BCG for high-risk non-muscle invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, IAP0971, given together with the standard BCG treatment for people with a high-risk type of bladder cancer that hasn't spread into the muscle. It's for patients who have already tried BCG and it didn't work well enough, and who either cannot have or choose not to have their bladder removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a high-risk form of bladder cancer that is only in the inner lining of the bladder (not in the muscle).
- You have already received BCG treatment for your bladder cancer and it stopped working or the cancer came back.
- You are not able to have surgery to remove your bladder, or you decide not to have that surgery.
- You are in generally good health, with a performance status of 0 or 1 on a scale that measures daily activity.
- Your major organs (like your kidneys, liver, and blood cell counts) must be working well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests an experimental drug called SPGL008, given alone or with BCG (a standard bladder cancer treatment), for people with high-risk non-muscle invasive bladder cancer who cannot or choose not to have their bladder removed. The study looks at safety and how well the drug works.
This trial tests a new drug, SIM0237, alone or with BCG, for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not respond to BCG treatment. The goal is to see if it is safe and works against the cancer.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.